The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults. The approval was supported by data from th ...
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
2d
GlobalData on MSNGenentech wins FDA approval for second stroke treatmentGenentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
2d
Zacks Investment Research on MSNRoche Gets FDA Approval for Acute Ischemic Stroke Drug for AdultsRoche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results